These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
464 related articles for article (PubMed ID: 23812802)
1. Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Kishi T; Iwata N CNS Drugs; 2013 Sep; 27(9):731-41. PubMed ID: 23812802 [TBL] [Abstract][Full Text] [Related]
2. Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials. Kishi T; Matsuda Y; Matsunaga S; Iwata N Neuropsychiatr Dis Treat; 2015; 11():419-34. PubMed ID: 25759585 [TBL] [Abstract][Full Text] [Related]
3. Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Kishi T; Matsuda Y; Iwata N PLoS One; 2014; 9(2):e88049. PubMed ID: 24505373 [TBL] [Abstract][Full Text] [Related]
4. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Oya K; Kishi T; Iwata N Hum Psychopharmacol; 2014 Sep; 29(5):483-91. PubMed ID: 25087702 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan. Kishi T; Ikuta T; Sakuma K; Okuya M; Iwata N J Psychiatr Res; 2021 Jun; 138():444-452. PubMed ID: 33964682 [TBL] [Abstract][Full Text] [Related]
7. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672 [TBL] [Abstract][Full Text] [Related]
8. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950 [TBL] [Abstract][Full Text] [Related]
9. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial. Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467 [TBL] [Abstract][Full Text] [Related]
10. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. Kishi T; Mukai T; Matsuda Y; Iwata N Neuromolecular Med; 2014 Mar; 16(1):61-9. PubMed ID: 23896722 [TBL] [Abstract][Full Text] [Related]
12. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
13. Quetiapine versus other atypical antipsychotics for schizophrenia. Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315 [TBL] [Abstract][Full Text] [Related]
14. Aripiprazole versus other atypical antipsychotics for schizophrenia. Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570 [TBL] [Abstract][Full Text] [Related]
15. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. Kishi T; Matsuda Y; Nakamura H; Iwata N J Psychiatr Res; 2013 Feb; 47(2):149-54. PubMed ID: 23131856 [TBL] [Abstract][Full Text] [Related]
16. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. Harvey RC; James AC; Shields GE CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. Citrome L; Meng X; Hochfeld M; Stahl SM Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738 [TBL] [Abstract][Full Text] [Related]
19. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Zhu Y; Krause M; Huhn M; Rothe P; Schneider-Thoma J; Chaimani A; Li C; Davis JM; Leucht S Lancet Psychiatry; 2017 Sep; 4(9):694-705. PubMed ID: 28736102 [TBL] [Abstract][Full Text] [Related]
20. [Pharmacological characteristics of perospirone hydrochloride, a novel antipsychotic agent]. Ohno Y Nihon Yakurigaku Zasshi; 2000 Oct; 116(4):225-31. PubMed ID: 11084919 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]